Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 140

1.

Who Provides Primary Care? An Assessment of HIV Patient and Provider Practices and Preferences.

Cheng QJ, Engelage EM, Grogan TR, Currier JS, Hoffman RM.

J AIDS Clin Res. 2014 Nov;5(11). pii: 366.

2.

Changes in Inflammation and Immune Activation with Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s.

Kelesidis T, Tran TT, Stein JH, Brown TT, Moser C, Ribaudo HJ, Dube MP, Murphy R, Yang OO, Currier JS, McComsey GA.

Clin Infect Dis. 2015 Apr 22. pii: civ327. [Epub ahead of print]

PMID:
25904376
3.

Concurrent Anemia and Elevated C-Reactive Protein Predicts HIV Clinical Treatment Failure, Including Tuberculosis, After Antiretroviral Therapy Initiation.

Shivakoti R, Yang WT, Gupte N, Berendes S, Rosa A, Cardoso SW, Mwelase N, Kanyama C, Pillay S, Samaneka W, Riviere C, Sugandhavesa P, Santos B, Poongulali S, Tripathy S, Bollinger RC, Currier JS, Tang AM, Semba RD, Christian P, Campbell TB, Gupta A; New Work Concept Sheet 319 and The Prospective Evaluation of Antiretrovirals in Resource-Limited Settings Study Team.

Clin Infect Dis. 2015 Mar 31. pii: civ265. [Epub ahead of print]

PMID:
25828994
4.

Comparison of the Metabolic Effects of Ritonavir-Boosted Darunavir or Atazanavir Versus Raltegravir, and the Impact of Ritonavir Plasma Exposure: ACTG 5257.

Ofotokun I, Na LH, Landovitz RJ, Ribaudo HJ, McComsey GA, Godfrey C, Aweeka F, Cohn SE, Sagar M, Kuritzkes DR, Brown TT, Patterson KB, Para MF, Leavitt RY, Villasis-Keever A, Baugh BP, Lennox JL, Currier JS; AIDS Clinical Trials Group (ACTG) A5257 Team; AIDS Clinical Trials Group ACTG A5257 Team.

Clin Infect Dis. 2015 Mar 12. pii: civ193. [Epub ahead of print]

PMID:
25767256
5.

The effect of hepatitis C virologic clearance on cardiovascular disease biomarkers in human immunodeficiency virus/hepatitis C virus coinfection.

Chew KW, Hua L, Bhattacharya D, Butt AA, Bornfleth L, Chung RT, Andersen JW, Currier JS.

Open Forum Infect Dis. 2014 Dec 3;1(3):ofu104. doi: 10.1093/ofid/ofu104. eCollection 2014 Dec.

6.

A high throughput biochemical fluorometric method for measuring lipid peroxidation in HDL.

Kelesidis T, Roberts CK, Huynh D, Martínez-Maza O, Currier JS, Reddy ST, Yang OO.

PLoS One. 2014 Nov 4;9(11):e111716. doi: 10.1371/journal.pone.0111716. eCollection 2014.

7.

Summaries for patients. Nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1.

Lennox JL, Landovitz RJ, Ribaudo HJ, Ofotokun I, Na LH, Godfrey C, Kuritzkes DR, Sagar M, Brown TT, Cohn SE, McComsey GA, Aweeka F, Fichtenbaum CJ, Presti RM, Koletar SL, Haas DW, Patterson KB, Benson CA, Baugh BP, Leavitt RY, Rooney JF, Seekins D, Currier JS; ACTG A5257 Team.

Ann Intern Med. 2014 Oct 7;161(7):I-22. doi: 10.7326/P14-9035. No abstract available.

PMID:
25285557
8.

Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial.

Lennox JL, Landovitz RJ, Ribaudo HJ, Ofotokun I, Na LH, Godfrey C, Kuritzkes DR, Sagar M, Brown TT, Cohn SE, McComsey GA, Aweeka F, Fichtenbaum CJ, Presti RM, Koletar SL, Haas DW, Patterson KB, Benson CA, Baugh BP, Leavitt RY, Rooney JF, Seekins D, Currier JS; ACTG A5257 Team.

Ann Intern Med. 2014 Oct 7;161(7):461-71. doi: 10.7326/M14-1084. Erratum in: Ann Intern Med. 2014 Nov 4;161(9):680.

9.

Dyslipidemia and cardiovascular risk in human immunodeficiency virus infection.

Kelesidis T, Currier JS.

Endocrinol Metab Clin North Am. 2014 Sep;43(3):665-84. doi: 10.1016/j.ecl.2014.06.003.

PMID:
25169560
10.

Psychosocial predictors of non-adherence and treatment failure in a large scale multi-national trial of antiretroviral therapy for HIV: data from the ACTG A5175/PEARLS trial.

Safren SA, Biello KB, Smeaton L, Mimiaga MJ, Walawander A, Lama JR, Rana A, Nyirenda M, Kayoyo VM, Samaneka W, Joglekar A, Celentano D, Martinez A, Remmert JE, Nair A, Lalloo UG, Kumarasamy N, Hakim J, Campbell TB; PEARLS (ACTG A5175) Study Team.

PLoS One. 2014 Aug 25;9(8):e104178. doi: 10.1371/journal.pone.0104178. eCollection 2014.

11.

Proteinuria is associated with neurocognitive impairment in antiretroviral therapy treated HIV-infected individuals.

Kalayjian RC, Wu K, Evans S, Clifford DB, Pallaki M, Currier JS, Smryzynski M.

J Acquir Immune Defic Syndr. 2014 Sep 1;67(1):30-5. doi: 10.1097/QAI.0000000000000237.

PMID:
25118793
12.

Role of RANKL-RANK/osteoprotegerin pathway in cardiovascular and bone disease associated with HIV infection.

Kelesidis T, Currier JS, Yang OO, Brown TT.

AIDS Rev. 2014 Jul-Sep;16(3):123-33. Review.

PMID:
25102334
13.

Urinary eicosanoid metabolites in HIV-infected women with central obesity switching to raltegravir: an analysis from the women, integrase, and fat accumulation trial.

Hulgan T, Boger MS, Liao DH, McComsey GA, Wanke CA, Mangili A, Walmsley SL, McCreath H, Milne GL, Sanchez SC, Currier JS, Lake JE.

Mediators Inflamm. 2014;2014:803095. doi: 10.1155/2014/803095. Epub 2014 Jun 1.

14.

CROI 2014: viral hepatitis and complications of HIV disease and antiretroviral therapy.

Luetkemeyer AF, Havlir DV, Currier JS.

Top Antivir Med. 2014 May;22(2):602-15.

15.

Antiretroviral therapy and efficacy after virologic failure on first-line boosted protease inhibitor regimens.

Zheng Y, Hughes MD, Lockman S, Benson CA, Hosseinipour MC, Campbell TB, Gulick RM, Daar ES, Sax PE, Riddler SA, Haubrich R, Salata RA, Currier JS.

Clin Infect Dis. 2014 Sep 15;59(6):888-96. doi: 10.1093/cid/ciu367. Epub 2014 May 19.

PMID:
24842909
16.

Arterial disease in patients with human immunodeficiency virus infection: what has imaging taught us?

Stein JH, Currier JS, Hsue PY.

JACC Cardiovasc Imaging. 2014 May;7(5):515-25. doi: 10.1016/j.jcmg.2013.08.019. Review.

17.

HIV and atherosclerosis: moving from associations to mechanisms and interventions.

Currier JS, Stein JH.

Ann Intern Med. 2014 Apr 1;160(7):509-10. doi: 10.7326/M14-0378. No abstract available.

PMID:
24687073
18.

Immune activation markers in peripartum women in Botswana: association with feeding strategy and maternal morbidity.

Russell ES, Mohammed T, Smeaton L, Jorowe B, MacLeod IJ, Hoffman RM, Currier JS, Moyo S, Essex M, Lockman S.

PLoS One. 2014 Mar 21;9(3):e89928. doi: 10.1371/journal.pone.0089928. eCollection 2014.

19.

HDL redox activity is increased in HIV-infected men in association with macrophage activation and non-calcified coronary atherosclerotic plaque.

Zanni MV, Kelesidis T, Fitzgerald ML, Lo J, Abbara S, Wai B, Marmarelis E, Hernandez NJ, Yang OO, Currier JS, Grinspoon SK.

Antivir Ther. 2014;19(8):805-11. doi: 10.3851/IMP2756. Epub 2014 Feb 17.

PMID:
24535655
20.

Switch to raltegravir decreases soluble CD14 in virologically suppressed overweight women: the Women, Integrase and Fat Accumulation Trial.

Lake JE, McComsey GA, Hulgan T, Wanke CA, Mangili A, Walmsley SL, Stramotas SA, Tracy R, Currier JS.

HIV Med. 2014 Aug;15(7):431-41. doi: 10.1111/hiv.12128. Epub 2014 Feb 10.

PMID:
24506429
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk